肝硬化患者血清TGF-β1、IL-10、IL-12和IL-18检测的应用价值

摘要

Objective To asses the clinical significance of the changes on serum TGF-β1, ,IL-10, IL-12 and IL-18 levels in patients with liver cirrhosis. Methods Determined serum TGF-β1 IL-10, IL-18 levels with ELISA in 66 patients with liver cirrhosis (30 cases complicated with ascites, 36cases without ascitea) and 35 nannal controls. Results Serum TGF~β1 ,TL-10,IL-12 and IL-18 levels were significantly higher in all the patients with liver cirrhosis than those in controls (P<0.01). Serum TGF-β1 level showed positive correlation with IL-10,IL-12 and IL-18(r =0.5018, 0.5742, 0.6011 ,P <0.01). Conclusion Detection of serum TGF-β1 , TL-10,IL-12 and IL-18 levels may help to evaluate of disease process and therapeutic efficacy. Therefore, provides impotant clinical value in patients with liver cirrhosis.%目的:详述肝硬化患者血清TGF-β1、IL-10、IL-12和IL-18水平的变化及临床意义.方法:应用酶联法对66例肝硬化患者(其中30例为肝硬化腹腔积液组,36例为肝硬化无腹腔积液组)进行了血清TGF-β1、IL-10、IL-12和IL-18测定并与35例正常人作比较.结果:肝硬化患者血清TGF-β1、IL-10、IL-12和IL-18水平均非常显著地高于正常人组(P<0.01),尤以肝硬化腹腔积液组为甚.肝硬化患者血清TGF-β1水平与IL-10、IL-12和IL-18水平呈正相关(r=0.5018、0.5742、0.6011,P<0.01).结论:检测肝硬化患者血清TGF-β1、IL-10、IL-12和IL-18水平的变化有助于对疾病变化过程和治疗功效的评估,因而可提供重要的临床价值.